Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF

被引:25
作者
Cleland, John G. F. [1 ]
Coletta, Alison P. [1 ]
Clark, Andrew L. [1 ]
机构
[1] Univ Hull, Dept Cardiol, Castle Hill Hosp, Kingston Upon Hull HU15 5JQ, Yorks, England
关键词
FIX-CHF-4; selective cardiac myosin activator; OPT-CHF;
D O I
10.1016/j.ejheart.2006.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the Heart Failure Society of America meeting held in Seattle in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. Devices designed to improve cardiac contractility may have improved exercise tolerance, and quality of life in the FIX-CHF-4 study; however, uncertainties in trial interpretation exist. The results of a study reporting the first administration of the selective myosin activator CK-1827452 to human volunteers, support the initiation of clinical trials in heart failure patients. In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels. (c) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
引用
收藏
页码:764 / 766
页数:3
相关论文
共 10 条
[1]  
ANDERSON RL, 2006, J CARD FAIL, V12
[2]   Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? [J].
Doehner, W ;
Anker, SD .
HEART, 2005, 91 (06) :707-709
[3]   Hyperuricemia and adverse outcomes in cardiovascular disease: Potential for therapeutic intervention [J].
Andrew R. Gavin ;
Allan D. Struthers .
American Journal of Cardiovascular Drugs, 2003, 3 (5) :309-314
[4]   Electrical signals applied during the absolute refractory period - An investigational treatment for advanced heart failure in patients with normal QRS duration [J].
Lawo, T ;
Borggrefe, M ;
Butter, C ;
Hindricks, G ;
Schmidinger, H ;
Mika, Y ;
Burkhoff, D ;
Pappone, C ;
Sabbah, HN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (12) :2229-2236
[5]  
NEELAGARU SB, 2006, J CARD FAIL, V12
[6]   First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: Mid-term safety and efficacy results from a multicenter study [J].
Pappone, C ;
Augello, G ;
Rosanio, S ;
Vicedomini, G ;
Santinelli, V ;
Romano, M ;
Agricola, E ;
Maggi, F ;
Buchmayr, G ;
Moretti, G ;
Mika, Y ;
Ben-Haim, SA ;
Wolzt, M ;
Stix, G ;
Schmidinger, H .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (04) :418-427
[7]   The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure [J].
Reyes, AJ .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (04) :461-467
[8]   Treating heart failure with cardiac contractility modulation electrical signals [J].
Sabbah H.N. ;
Gupta R.C. ;
Rastogi S. ;
Mishra S. ;
Mika Y. ;
Burkhoff D. .
Current Heart Failure Reports, 2006, 3 (1) :21-24
[9]  
SHEN YT, 2006, J CARD FAIL, V12
[10]   Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study [J].
Struthers, AD ;
Donnan, PT ;
Lindsay, P ;
McNaughton, D ;
Broomhall, J ;
MacDonald, TM .
HEART, 2002, 87 (03) :229-234